This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
FORUM Pharmaceuticals, Inc.
Drug Names(s): MT-4666, EVP-6124
Description: EVP-6124 is a partial agonist of the alpha-7 nicotinic acetylcholine receptor, with good CNS penetration. Alpha-7 nicotinic acetylcholine receptors are thought to be involved in memory, cognition, synaptic plasticity, and neuronal survival. They not only mediate cholinergic transmission but also influence signaling at noncholinergic synapses (such as glutamate and serotonin). In addition, they may mediate dopamine release in response to nicotine, particularly in the nucleus accumbens, part of the classic reward pathway.
Deal Structure: In November of 2004, EnVivo Pharmaceuticals licensed from Bayer Healthcare the exclusive rights to their alpha 7 agonist program and considerable patent estate. EnVivo identified EVP-6124 as a highly CNS-penetrant, orally bio-available, potent nicotinic alpha 7 agonists in Q3 2005.
In April 2009, EnVivo Pharmaceuticals announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) for the development and commercialization of EVP-6124 in Japan and several other Asian countries. Under the terms of the agreement, MTPC has obtained exclusive rights to develop and commercialize EnVivo's alpha-7 nicotinic acetylcholine receptor agonists such as EVP-6124 in Japan, Korea, Taiwan, Indonesia and several other Asian markets. EnVivo will receive an initial license payment and is eligible for clinical and regulatory milestones, as well as several commercial milestones. EnVivo also will receive royalties on sales of EVP-6124 in the MTPC territory.
Partners: Mitsubishi Tanabe Pharma Corporation
Additional information available to subscribers only: